Cellectis (CLLS) EBIT (2015 - 2026)
Cellectis' (CLLS) quarterly EBIT came in at -$25.2 million in Q1 2026, down 77.49% year-on-year from -$111.8 million in Q1 2025, and down 45.04% quarter-over-quarter from -$17.4 million in Q4 2025.
Cellectis (CLLS) EBIT (2015 - 2026) Analysis & Trends
Cellectis' EBIT history runs 12 years deep, the most recent figure standing at -$25.2 million for Q1 2026.
- On a quarterly basis, EBIT fell 77.49% year-over-year to -$25.2 million in Q1 2026; TTM through Mar 2026 was -$44.1 million, a 16.61% increase from a year earlier, with the FY2025 full-year figure at -$59.6 million, changed 0.0% from the prior year.
- EBIT slipped to -$25.2 million in Q1 2026 per CLLS's latest filing, from -$17.4 million in the prior quarter.
- Across five years, EBIT topped out at $8.0 million in Q3 2025 and bottomed at -$29.6 million in Q4 2023.
- The 5-year median for EBIT is -$20.7 million (2023), against an average of -$17.9 million.
- Across the five-year window, EBIT plunged 422.6% in 2023 and jumped 174.67% in 2025, its largest moves.
- Year by year, EBIT stood at -$5.7 million in 2022, then plunged by 422.6% to -$29.6 million in 2023, then soared by 63.89% to -$10.7 million in 2024, then tumbled by 62.47% to -$17.4 million in 2025, then sank by 45.04% to -$25.2 million in 2026.
- Per Business Quant, the three latest CLLS EBIT figures stand at -$25.2 million (Q1 2026), -$17.4 million (Q4 2025), and $8.0 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | Cellectis | 281.48 Mn | 95.81 Mn | - | -25.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -25.17 Mn |
| Dec 31, 2025 | -17.35 Mn |
| Sep 30, 2025 | 8.04 Mn |
| Jun 30, 2025 | -9.59 Mn |
| Mar 31, 2025 | -14.18 Mn |
| Dec 31, 2024 | -10.68 Mn |
| Sep 30, 2024 | -10.77 Mn |
| Jun 30, 2024 | -17.21 Mn |
| Mar 31, 2024 | -20.89 Mn |
| Dec 31, 2023 | -29.58 Mn |
| Sep 30, 2023 | -20.67 Mn |
| Jun 30, 2023 | -23.62 Mn |
| Mar 31, 2023 | -23.43 Mn |
| Dec 31, 2022 | -5.66 Mn |
| Sep 30, 2022 | -27.35 Mn |
| Jun 30, 2022 | -27.31 Mn |
| Mar 31, 2022 | -29.23 Mn |
| Dec 31, 2021 | -24.56 Mn |
| Sep 30, 2021 | -42.37 Mn |
| Jun 30, 2021 | -37.48 Mn |